Effect of Pharmacogenetics on Renal Outcomes of Heart Failure Patients with Reduced Ejection Fraction (HFrEF) in Response to Dapagliflozin Article Swipe
Neven Sarhan
,
Mona F. Schaalan
,
Azza A. K. El‐Sheikh
,
Bassem Zarif
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.3390/pharmaceutics17080959
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.3390/pharmaceutics17080959
Background/Objectives: Heart failure with reduced ejection fraction (HFrEF) is associated with significant renal complications, affecting disease progression and patient outcomes. Sodium-glucose co-transporter-2 (SGLT2) inhibitors have emerged as a key therapeutic strategy, offering cardiovascular and renal benefits in these patients. However, interindividual variability in response to dapagliflozin underscores the role of pharmacogenetics in optimizing treatment efficacy. This study investigates the influence of genetic polymorphisms on renal outcomes in HFrEF patients treated with dapagliflozin, focusing on variations in genes such as SLC5A2, UMOD, KCNJ11, and ACE. Methods: This prospective, observational cohort study was conducted at the National Heart Institute, Cairo, Egypt, enrolling 200 patients with HFrEF. Genotyping of selected single nucleotide polymorphisms (SNPs) was performed using TaqMan™ assays. Renal function, including estimated glomerular filtration rate (eGFR), Kidney Injury Molecule-1 (KIM-1), and Neutrophil Gelatinase-Associated Lipocalin (NGAL) levels, was assessed at baseline and after six months of dapagliflozin therapy. Results: Significant associations were found between genetic variants and renal outcomes. Patients with AA genotype of rs3813008 (SLC5A2) exhibited the greatest improvement in eGFR (+7.2 mL ± 6.5, p = 0.004) and reductions in KIM-1 (−0.13 pg/mL ± 0.49, p < 0.0001) and NGAL (−6.1 pg/mL ± 15.4, p < 0.0001). Similarly, rs12917707 (UMOD) TT genotypes showed improved renal function. However, rs5219 (KCNJ11) showed no significant impact on renal outcomes. Conclusions: Pharmacogenetic variations influenced renal response to dapagliflozin in HFrEF patients, particularly in SLC5A2 and UMOD genes. These findings highlighted the potential of personalized medicine in optimizing therapy for HFrEF patients with renal complications.
Related Topics
Concepts
Medicine
Renal function
Ejection fraction
Pharmacogenetics
Dapagliflozin
Internal medicine
Heart failure
Single-nucleotide polymorphism
Urology
Cardiology
Genotype
Endocrinology
Biology
Diabetes mellitus
Biochemistry
Gene
Type 2 diabetes
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.3390/pharmaceutics17080959
- https://www.mdpi.com/1999-4923/17/8/959/pdf?version=1753367343
- OA Status
- gold
- References
- 33
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4412629218
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4412629218Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.3390/pharmaceutics17080959Digital Object Identifier
- Title
-
Effect of Pharmacogenetics on Renal Outcomes of Heart Failure Patients with Reduced Ejection Fraction (HFrEF) in Response to DapagliflozinWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-07-24Full publication date if available
- Authors
-
Neven Sarhan, Mona F. Schaalan, Azza A. K. El‐Sheikh, Bassem ZarifList of authors in order
- Landing page
-
https://doi.org/10.3390/pharmaceutics17080959Publisher landing page
- PDF URL
-
https://www.mdpi.com/1999-4923/17/8/959/pdf?version=1753367343Direct link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://www.mdpi.com/1999-4923/17/8/959/pdf?version=1753367343Direct OA link when available
- Concepts
-
Medicine, Renal function, Ejection fraction, Pharmacogenetics, Dapagliflozin, Internal medicine, Heart failure, Single-nucleotide polymorphism, Urology, Cardiology, Genotype, Endocrinology, Biology, Diabetes mellitus, Biochemistry, Gene, Type 2 diabetesTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- References (count)
-
33Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4412629218 |
|---|---|
| doi | https://doi.org/10.3390/pharmaceutics17080959 |
| ids.doi | https://doi.org/10.3390/pharmaceutics17080959 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/40870982 |
| ids.openalex | https://openalex.org/W4412629218 |
| fwci | 0.0 |
| type | article |
| title | Effect of Pharmacogenetics on Renal Outcomes of Heart Failure Patients with Reduced Ejection Fraction (HFrEF) in Response to Dapagliflozin |
| awards[0].id | https://openalex.org/G6510816319 |
| awards[0].funder_id | https://openalex.org/F4320322484 |
| awards[0].display_name | |
| awards[0].funder_award_id | PNURSP2025R91 |
| awards[0].funder_display_name | Princess Nourah Bint Abdulrahman University |
| biblio.issue | 8 |
| biblio.volume | 17 |
| biblio.last_page | 959 |
| biblio.first_page | 959 |
| topics[0].id | https://openalex.org/T10401 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2712 |
| topics[0].subfield.display_name | Endocrinology, Diabetes and Metabolism |
| topics[0].display_name | Diabetes Treatment and Management |
| topics[1].id | https://openalex.org/T10839 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9993000030517578 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2746 |
| topics[1].subfield.display_name | Surgery |
| topics[1].display_name | Pancreatic function and diabetes |
| topics[2].id | https://openalex.org/T11193 |
| topics[2].field.id | https://openalex.org/fields/13 |
| topics[2].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[2].score | 0.9819999933242798 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/1314 |
| topics[2].subfield.display_name | Physiology |
| topics[2].display_name | Adenosine and Purinergic Signaling |
| funders[0].id | https://openalex.org/F4320322484 |
| funders[0].ror | https://ror.org/05b0cyh02 |
| funders[0].display_name | Princess Nourah Bint Abdulrahman University |
| is_xpac | False |
| apc_list.value | 2600 |
| apc_list.currency | CHF |
| apc_list.value_usd | 2815 |
| apc_paid.value | 2600 |
| apc_paid.currency | CHF |
| apc_paid.value_usd | 2815 |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.7868441343307495 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C159641895 |
| concepts[1].level | 2 |
| concepts[1].score | 0.7265991568565369 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q108377937 |
| concepts[1].display_name | Renal function |
| concepts[2].id | https://openalex.org/C78085059 |
| concepts[2].level | 3 |
| concepts[2].score | 0.6771050691604614 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q641303 |
| concepts[2].display_name | Ejection fraction |
| concepts[3].id | https://openalex.org/C55775858 |
| concepts[3].level | 4 |
| concepts[3].score | 0.6497557163238525 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q1152227 |
| concepts[3].display_name | Pharmacogenetics |
| concepts[4].id | https://openalex.org/C2777422806 |
| concepts[4].level | 4 |
| concepts[4].score | 0.6391589045524597 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q409898 |
| concepts[4].display_name | Dapagliflozin |
| concepts[5].id | https://openalex.org/C126322002 |
| concepts[5].level | 1 |
| concepts[5].score | 0.603096604347229 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[5].display_name | Internal medicine |
| concepts[6].id | https://openalex.org/C2778198053 |
| concepts[6].level | 2 |
| concepts[6].score | 0.44414353370666504 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q181754 |
| concepts[6].display_name | Heart failure |
| concepts[7].id | https://openalex.org/C153209595 |
| concepts[7].level | 4 |
| concepts[7].score | 0.44145268201828003 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q501128 |
| concepts[7].display_name | Single-nucleotide polymorphism |
| concepts[8].id | https://openalex.org/C126894567 |
| concepts[8].level | 1 |
| concepts[8].score | 0.38032102584838867 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q105650 |
| concepts[8].display_name | Urology |
| concepts[9].id | https://openalex.org/C164705383 |
| concepts[9].level | 1 |
| concepts[9].score | 0.3225051462650299 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q10379 |
| concepts[9].display_name | Cardiology |
| concepts[10].id | https://openalex.org/C135763542 |
| concepts[10].level | 3 |
| concepts[10].score | 0.25580835342407227 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q106016 |
| concepts[10].display_name | Genotype |
| concepts[11].id | https://openalex.org/C134018914 |
| concepts[11].level | 1 |
| concepts[11].score | 0.21395960450172424 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q162606 |
| concepts[11].display_name | Endocrinology |
| concepts[12].id | https://openalex.org/C86803240 |
| concepts[12].level | 0 |
| concepts[12].score | 0.10235962271690369 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[12].display_name | Biology |
| concepts[13].id | https://openalex.org/C555293320 |
| concepts[13].level | 2 |
| concepts[13].score | 0.07935529947280884 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q12206 |
| concepts[13].display_name | Diabetes mellitus |
| concepts[14].id | https://openalex.org/C55493867 |
| concepts[14].level | 1 |
| concepts[14].score | 0.0 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q7094 |
| concepts[14].display_name | Biochemistry |
| concepts[15].id | https://openalex.org/C104317684 |
| concepts[15].level | 2 |
| concepts[15].score | 0.0 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q7187 |
| concepts[15].display_name | Gene |
| concepts[16].id | https://openalex.org/C2777180221 |
| concepts[16].level | 3 |
| concepts[16].score | 0.0 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q3025883 |
| concepts[16].display_name | Type 2 diabetes |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.7868441343307495 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/renal-function |
| keywords[1].score | 0.7265991568565369 |
| keywords[1].display_name | Renal function |
| keywords[2].id | https://openalex.org/keywords/ejection-fraction |
| keywords[2].score | 0.6771050691604614 |
| keywords[2].display_name | Ejection fraction |
| keywords[3].id | https://openalex.org/keywords/pharmacogenetics |
| keywords[3].score | 0.6497557163238525 |
| keywords[3].display_name | Pharmacogenetics |
| keywords[4].id | https://openalex.org/keywords/dapagliflozin |
| keywords[4].score | 0.6391589045524597 |
| keywords[4].display_name | Dapagliflozin |
| keywords[5].id | https://openalex.org/keywords/internal-medicine |
| keywords[5].score | 0.603096604347229 |
| keywords[5].display_name | Internal medicine |
| keywords[6].id | https://openalex.org/keywords/heart-failure |
| keywords[6].score | 0.44414353370666504 |
| keywords[6].display_name | Heart failure |
| keywords[7].id | https://openalex.org/keywords/single-nucleotide-polymorphism |
| keywords[7].score | 0.44145268201828003 |
| keywords[7].display_name | Single-nucleotide polymorphism |
| keywords[8].id | https://openalex.org/keywords/urology |
| keywords[8].score | 0.38032102584838867 |
| keywords[8].display_name | Urology |
| keywords[9].id | https://openalex.org/keywords/cardiology |
| keywords[9].score | 0.3225051462650299 |
| keywords[9].display_name | Cardiology |
| keywords[10].id | https://openalex.org/keywords/genotype |
| keywords[10].score | 0.25580835342407227 |
| keywords[10].display_name | Genotype |
| keywords[11].id | https://openalex.org/keywords/endocrinology |
| keywords[11].score | 0.21395960450172424 |
| keywords[11].display_name | Endocrinology |
| keywords[12].id | https://openalex.org/keywords/biology |
| keywords[12].score | 0.10235962271690369 |
| keywords[12].display_name | Biology |
| keywords[13].id | https://openalex.org/keywords/diabetes-mellitus |
| keywords[13].score | 0.07935529947280884 |
| keywords[13].display_name | Diabetes mellitus |
| language | en |
| locations[0].id | doi:10.3390/pharmaceutics17080959 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S30283931 |
| locations[0].source.issn | 1999-4923 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 1999-4923 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Pharmaceutics |
| locations[0].source.host_organization | https://openalex.org/P4310310987 |
| locations[0].source.host_organization_name | Multidisciplinary Digital Publishing Institute |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310310987 |
| locations[0].source.host_organization_lineage_names | Multidisciplinary Digital Publishing Institute |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://www.mdpi.com/1999-4923/17/8/959/pdf?version=1753367343 |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Pharmaceutics |
| locations[0].landing_page_url | https://doi.org/10.3390/pharmaceutics17080959 |
| locations[1].id | pmid:40870982 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Pharmaceutics |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/40870982 |
| locations[2].id | pmh:oai:doaj.org/article:5f89119df6824c4f848ce0c26b6400ba |
| locations[2].is_oa | False |
| locations[2].source.id | https://openalex.org/S4306401280 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[2].source.host_organization | |
| locations[2].source.host_organization_name | |
| locations[2].license | |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | article |
| locations[2].license_id | |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Pharmaceutics, Vol 17, Iss 8, p 959 (2025) |
| locations[2].landing_page_url | https://doaj.org/article/5f89119df6824c4f848ce0c26b6400ba |
| locations[3].id | pmh:oai:europepmc.org:11197335 |
| locations[3].is_oa | True |
| locations[3].source.id | https://openalex.org/S4306400806 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | Europe PMC (PubMed Central) |
| locations[3].source.host_organization | https://openalex.org/I1303153112 |
| locations[3].source.host_organization_name | European Bioinformatics Institute |
| locations[3].source.host_organization_lineage | https://openalex.org/I1303153112 |
| locations[3].license | other-oa |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | Text |
| locations[3].license_id | https://openalex.org/licenses/other-oa |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | |
| locations[3].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/12389526 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5030560104 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-4067-5518 |
| authorships[0].author.display_name | Neven Sarhan |
| authorships[0].countries | EG |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I47853400 |
| authorships[0].affiliations[0].raw_affiliation_string | Clinical Pharmacy Department, Faculty of Pharmacy, Misr International University, Cairo 11314, Egypt |
| authorships[0].institutions[0].id | https://openalex.org/I47853400 |
| authorships[0].institutions[0].ror | https://ror.org/030vg1t69 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I47853400 |
| authorships[0].institutions[0].country_code | EG |
| authorships[0].institutions[0].display_name | Misr International University |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Neven Sarhan |
| authorships[0].is_corresponding | True |
| authorships[0].raw_affiliation_strings | Clinical Pharmacy Department, Faculty of Pharmacy, Misr International University, Cairo 11314, Egypt |
| authorships[1].author.id | https://openalex.org/A5005714824 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-8569-689X |
| authorships[1].author.display_name | Mona F. Schaalan |
| authorships[1].countries | EG |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I47853400 |
| authorships[1].affiliations[0].raw_affiliation_string | Clinical Pharmacy Department, Faculty of Pharmacy, Misr International University, Cairo 11314, Egypt |
| authorships[1].institutions[0].id | https://openalex.org/I47853400 |
| authorships[1].institutions[0].ror | https://ror.org/030vg1t69 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I47853400 |
| authorships[1].institutions[0].country_code | EG |
| authorships[1].institutions[0].display_name | Misr International University |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Mona F. Schaalan |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Clinical Pharmacy Department, Faculty of Pharmacy, Misr International University, Cairo 11314, Egypt |
| authorships[2].author.id | https://openalex.org/A5061137778 |
| authorships[2].author.orcid | https://orcid.org/0000-0003-3726-0386 |
| authorships[2].author.display_name | Azza A. K. El‐Sheikh |
| authorships[2].countries | SA |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I106778892 |
| authorships[2].affiliations[0].raw_affiliation_string | Basic Health Sciences Department, College of Medicine, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia |
| authorships[2].institutions[0].id | https://openalex.org/I106778892 |
| authorships[2].institutions[0].ror | https://ror.org/05b0cyh02 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I106778892 |
| authorships[2].institutions[0].country_code | SA |
| authorships[2].institutions[0].display_name | Princess Nourah bint Abdulrahman University |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Azza A. K. El-Sheikh |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Basic Health Sciences Department, College of Medicine, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia |
| authorships[3].author.id | https://openalex.org/A5080368245 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-0717-4084 |
| authorships[3].author.display_name | Bassem Zarif |
| authorships[3].countries | EG |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210151270, https://openalex.org/I4210160667 |
| authorships[3].affiliations[0].raw_affiliation_string | Cardiology Department, National Heart Institute, Ministry of Health and Population, Cairo 11796, Egypt |
| authorships[3].institutions[0].id | https://openalex.org/I4210160667 |
| authorships[3].institutions[0].ror | https://ror.org/04f90ax67 |
| authorships[3].institutions[0].type | government |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210160667 |
| authorships[3].institutions[0].country_code | EG |
| authorships[3].institutions[0].display_name | Ministry of Health and Population |
| authorships[3].institutions[1].id | https://openalex.org/I4210151270 |
| authorships[3].institutions[1].ror | https://ror.org/055273664 |
| authorships[3].institutions[1].type | healthcare |
| authorships[3].institutions[1].lineage | https://openalex.org/I4210151270 |
| authorships[3].institutions[1].country_code | EG |
| authorships[3].institutions[1].display_name | National Heart Institute |
| authorships[3].author_position | last |
| authorships[3].raw_author_name | Bassem Zarif |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Cardiology Department, National Heart Institute, Ministry of Health and Population, Cairo 11796, Egypt |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.mdpi.com/1999-4923/17/8/959/pdf?version=1753367343 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Effect of Pharmacogenetics on Renal Outcomes of Heart Failure Patients with Reduced Ejection Fraction (HFrEF) in Response to Dapagliflozin |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10401 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2712 |
| primary_topic.subfield.display_name | Endocrinology, Diabetes and Metabolism |
| primary_topic.display_name | Diabetes Treatment and Management |
| related_works | https://openalex.org/W2549923796, https://openalex.org/W4213008657, https://openalex.org/W102536597, https://openalex.org/W2338997164, https://openalex.org/W1506615841, https://openalex.org/W2187631938, https://openalex.org/W2033417941, https://openalex.org/W1705472263, https://openalex.org/W2161506066, https://openalex.org/W3035255089 |
| cited_by_count | 0 |
| locations_count | 4 |
| best_oa_location.id | doi:10.3390/pharmaceutics17080959 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S30283931 |
| best_oa_location.source.issn | 1999-4923 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 1999-4923 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Pharmaceutics |
| best_oa_location.source.host_organization | https://openalex.org/P4310310987 |
| best_oa_location.source.host_organization_name | Multidisciplinary Digital Publishing Institute |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310310987 |
| best_oa_location.source.host_organization_lineage_names | Multidisciplinary Digital Publishing Institute |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://www.mdpi.com/1999-4923/17/8/959/pdf?version=1753367343 |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Pharmaceutics |
| best_oa_location.landing_page_url | https://doi.org/10.3390/pharmaceutics17080959 |
| primary_location.id | doi:10.3390/pharmaceutics17080959 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S30283931 |
| primary_location.source.issn | 1999-4923 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 1999-4923 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Pharmaceutics |
| primary_location.source.host_organization | https://openalex.org/P4310310987 |
| primary_location.source.host_organization_name | Multidisciplinary Digital Publishing Institute |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310310987 |
| primary_location.source.host_organization_lineage_names | Multidisciplinary Digital Publishing Institute |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://www.mdpi.com/1999-4923/17/8/959/pdf?version=1753367343 |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Pharmaceutics |
| primary_location.landing_page_url | https://doi.org/10.3390/pharmaceutics17080959 |
| publication_date | 2025-07-24 |
| publication_year | 2025 |
| referenced_works | https://openalex.org/W4210937888, https://openalex.org/W4402766324, https://openalex.org/W4387051158, https://openalex.org/W4220837239, https://openalex.org/W3201369060, https://openalex.org/W3144902229, https://openalex.org/W4387527826, https://openalex.org/W2160471487, https://openalex.org/W2553261268, https://openalex.org/W2165019590, https://openalex.org/W4235972890, https://openalex.org/W2169174186, https://openalex.org/W2097620901, https://openalex.org/W2097532633, https://openalex.org/W6863218477, https://openalex.org/W3119956916, https://openalex.org/W2939222610, https://openalex.org/W6783267877, https://openalex.org/W4401195803, https://openalex.org/W2989624959, https://openalex.org/W2039712457, https://openalex.org/W2800723402, https://openalex.org/W2808725516, https://openalex.org/W3112405194, https://openalex.org/W4307890926, https://openalex.org/W3129868983, https://openalex.org/W2012911679, https://openalex.org/W3092617122, https://openalex.org/W4366419011, https://openalex.org/W3125331010, https://openalex.org/W3088173406, https://openalex.org/W4393239671, https://openalex.org/W2120798274 |
| referenced_works_count | 33 |
| abstract_inverted_index.= | 174 |
| abstract_inverted_index.a | 27 |
| abstract_inverted_index.p | 173, 184, 193 |
| abstract_inverted_index.AA | 158 |
| abstract_inverted_index.TT | 199 |
| abstract_inverted_index.as | 26, 78 |
| abstract_inverted_index.at | 92, 136 |
| abstract_inverted_index.in | 36, 42, 51, 66, 75, 167, 178, 223, 227, 240 |
| abstract_inverted_index.is | 8 |
| abstract_inverted_index.mL | 170 |
| abstract_inverted_index.no | 209 |
| abstract_inverted_index.of | 49, 60, 105, 142, 160, 237 |
| abstract_inverted_index.on | 63, 73, 212 |
| abstract_inverted_index.to | 44, 221 |
| abstract_inverted_index.± | 171, 182, 191 |
| abstract_inverted_index.200 | 100 |
| abstract_inverted_index.and | 17, 33, 82, 128, 138, 153, 176, 187, 229 |
| abstract_inverted_index.for | 243 |
| abstract_inverted_index.key | 28 |
| abstract_inverted_index.six | 140 |
| abstract_inverted_index.the | 47, 58, 93, 164, 235 |
| abstract_inverted_index.was | 90, 111, 134 |
| abstract_inverted_index.< | 185, 194 |
| abstract_inverted_index.6.5, | 172 |
| abstract_inverted_index.ACE. | 83 |
| abstract_inverted_index.NGAL | 188 |
| abstract_inverted_index.This | 55, 85 |
| abstract_inverted_index.UMOD | 230 |
| abstract_inverted_index.eGFR | 168 |
| abstract_inverted_index.have | 24 |
| abstract_inverted_index.rate | 122 |
| abstract_inverted_index.role | 48 |
| abstract_inverted_index.such | 77 |
| abstract_inverted_index.were | 148 |
| abstract_inverted_index.with | 3, 10, 70, 102, 157, 246 |
| abstract_inverted_index.(+7.2 | 169 |
| abstract_inverted_index.0.49, | 183 |
| abstract_inverted_index.15.4, | 192 |
| abstract_inverted_index.HFrEF | 67, 224, 244 |
| abstract_inverted_index.Heart | 1, 95 |
| abstract_inverted_index.KIM-1 | 179 |
| abstract_inverted_index.Renal | 116 |
| abstract_inverted_index.These | 232 |
| abstract_inverted_index.UMOD, | 80 |
| abstract_inverted_index.after | 139 |
| abstract_inverted_index.found | 149 |
| abstract_inverted_index.genes | 76 |
| abstract_inverted_index.pg/mL | 181, 190 |
| abstract_inverted_index.renal | 12, 34, 64, 154, 203, 213, 219, 247 |
| abstract_inverted_index.study | 56, 89 |
| abstract_inverted_index.these | 37 |
| abstract_inverted_index.using | 113 |
| abstract_inverted_index.(NGAL) | 132 |
| abstract_inverted_index.(SNPs) | 110 |
| abstract_inverted_index.(UMOD) | 198 |
| abstract_inverted_index.0.004) | 175 |
| abstract_inverted_index.Cairo, | 97 |
| abstract_inverted_index.Egypt, | 98 |
| abstract_inverted_index.HFrEF. | 103 |
| abstract_inverted_index.Injury | 125 |
| abstract_inverted_index.Kidney | 124 |
| abstract_inverted_index.SLC5A2 | 228 |
| abstract_inverted_index.cohort | 88 |
| abstract_inverted_index.genes. | 231 |
| abstract_inverted_index.impact | 211 |
| abstract_inverted_index.months | 141 |
| abstract_inverted_index.rs5219 | 206 |
| abstract_inverted_index.showed | 201, 208 |
| abstract_inverted_index.single | 107 |
| abstract_inverted_index.(HFrEF) | 7 |
| abstract_inverted_index.(SGLT2) | 22 |
| abstract_inverted_index.(eGFR), | 123 |
| abstract_inverted_index.(−6.1 | 189 |
| abstract_inverted_index.0.0001) | 186 |
| abstract_inverted_index.KCNJ11, | 81 |
| abstract_inverted_index.SLC5A2, | 79 |
| abstract_inverted_index.assays. | 115 |
| abstract_inverted_index.between | 150 |
| abstract_inverted_index.disease | 15 |
| abstract_inverted_index.emerged | 25 |
| abstract_inverted_index.failure | 2 |
| abstract_inverted_index.genetic | 61, 151 |
| abstract_inverted_index.levels, | 133 |
| abstract_inverted_index.patient | 18 |
| abstract_inverted_index.reduced | 4 |
| abstract_inverted_index.therapy | 242 |
| abstract_inverted_index.treated | 69 |
| abstract_inverted_index.(KCNJ11) | 207 |
| abstract_inverted_index.(KIM-1), | 127 |
| abstract_inverted_index.(SLC5A2) | 162 |
| abstract_inverted_index.(−0.13 | 180 |
| abstract_inverted_index.0.0001). | 195 |
| abstract_inverted_index.However, | 39, 205 |
| abstract_inverted_index.Methods: | 84 |
| abstract_inverted_index.National | 94 |
| abstract_inverted_index.Patients | 156 |
| abstract_inverted_index.Results: | 145 |
| abstract_inverted_index.assessed | 135 |
| abstract_inverted_index.baseline | 137 |
| abstract_inverted_index.benefits | 35 |
| abstract_inverted_index.ejection | 5 |
| abstract_inverted_index.findings | 233 |
| abstract_inverted_index.focusing | 72 |
| abstract_inverted_index.fraction | 6 |
| abstract_inverted_index.genotype | 159 |
| abstract_inverted_index.greatest | 165 |
| abstract_inverted_index.improved | 202 |
| abstract_inverted_index.medicine | 239 |
| abstract_inverted_index.offering | 31 |
| abstract_inverted_index.outcomes | 65 |
| abstract_inverted_index.patients | 68, 101, 245 |
| abstract_inverted_index.response | 43, 220 |
| abstract_inverted_index.selected | 106 |
| abstract_inverted_index.therapy. | 144 |
| abstract_inverted_index.variants | 152 |
| abstract_inverted_index.Lipocalin | 131 |
| abstract_inverted_index.TaqMan™ | 114 |
| abstract_inverted_index.affecting | 14 |
| abstract_inverted_index.conducted | 91 |
| abstract_inverted_index.efficacy. | 54 |
| abstract_inverted_index.enrolling | 99 |
| abstract_inverted_index.estimated | 119 |
| abstract_inverted_index.exhibited | 163 |
| abstract_inverted_index.function, | 117 |
| abstract_inverted_index.function. | 204 |
| abstract_inverted_index.genotypes | 200 |
| abstract_inverted_index.including | 118 |
| abstract_inverted_index.influence | 59 |
| abstract_inverted_index.outcomes. | 19, 155, 214 |
| abstract_inverted_index.patients, | 225 |
| abstract_inverted_index.patients. | 38 |
| abstract_inverted_index.performed | 112 |
| abstract_inverted_index.potential | 236 |
| abstract_inverted_index.rs3813008 | 161 |
| abstract_inverted_index.strategy, | 30 |
| abstract_inverted_index.treatment | 53 |
| abstract_inverted_index.Genotyping | 104 |
| abstract_inverted_index.Institute, | 96 |
| abstract_inverted_index.Molecule-1 | 126 |
| abstract_inverted_index.Neutrophil | 129 |
| abstract_inverted_index.Similarly, | 196 |
| abstract_inverted_index.associated | 9 |
| abstract_inverted_index.filtration | 121 |
| abstract_inverted_index.glomerular | 120 |
| abstract_inverted_index.influenced | 218 |
| abstract_inverted_index.inhibitors | 23 |
| abstract_inverted_index.nucleotide | 108 |
| abstract_inverted_index.optimizing | 52, 241 |
| abstract_inverted_index.reductions | 177 |
| abstract_inverted_index.rs12917707 | 197 |
| abstract_inverted_index.variations | 74, 217 |
| abstract_inverted_index.Significant | 146 |
| abstract_inverted_index.highlighted | 234 |
| abstract_inverted_index.improvement | 166 |
| abstract_inverted_index.progression | 16 |
| abstract_inverted_index.significant | 11, 210 |
| abstract_inverted_index.therapeutic | 29 |
| abstract_inverted_index.underscores | 46 |
| abstract_inverted_index.variability | 41 |
| abstract_inverted_index.Conclusions: | 215 |
| abstract_inverted_index.associations | 147 |
| abstract_inverted_index.investigates | 57 |
| abstract_inverted_index.particularly | 226 |
| abstract_inverted_index.personalized | 238 |
| abstract_inverted_index.prospective, | 86 |
| abstract_inverted_index.dapagliflozin | 45, 143, 222 |
| abstract_inverted_index.observational | 87 |
| abstract_inverted_index.polymorphisms | 62, 109 |
| abstract_inverted_index.Sodium-glucose | 20 |
| abstract_inverted_index.cardiovascular | 32 |
| abstract_inverted_index.complications, | 13 |
| abstract_inverted_index.complications. | 248 |
| abstract_inverted_index.dapagliflozin, | 71 |
| abstract_inverted_index.Pharmacogenetic | 216 |
| abstract_inverted_index.interindividual | 40 |
| abstract_inverted_index.co-transporter-2 | 21 |
| abstract_inverted_index.pharmacogenetics | 50 |
| abstract_inverted_index.Gelatinase-Associated | 130 |
| abstract_inverted_index.Background/Objectives: | 0 |
| cited_by_percentile_year | |
| corresponding_author_ids | https://openalex.org/A5030560104 |
| countries_distinct_count | 2 |
| institutions_distinct_count | 4 |
| corresponding_institution_ids | https://openalex.org/I47853400 |
| citation_normalized_percentile.value | 0.40189826 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |